Navigation Links
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Date:5/31/2008

y prednisone (5 mg) as a first-line treatment is being evaluated in 30 patients with metastatic HRPC. PSA response (defined as a PSA reduction of at least 50 percent from baseline) is the primary endpoint; secondary endpoints include safety, response rate, time to progression and overall survival. The trial completed enrollment in December 2007.

Results to date have shown a PSA response in 18 of 26 (69 percent) evaluable patients. Furthermore, PSA levels have normalized in six patients (21 percent). The combination of picoplatin and docetaxel can be safely administered with manageable and reversible neutropenia as the main hematologic toxicity. These data confirm earlier results observed in the Phase 1 trial. In contrast to picoplatin monotherapy, thrombocytopenia was less severe and less frequent. Neurotoxicity has not been observed in this study.

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the ongoing Phase 2 clinical trial in HRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic colorectal cancer. Oral
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Inferior Vena Cava (IVC) Filters - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... projected to reach US$435 million by 2016. The ... (2015) of the global value while Europe ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... of Cervical Cancer and Other Human,Papillomavirus Related Diseases ... Phase III Clinical Studies Which Included More Than,17,000 ... the most comprehensive,and robust clinical data for any ... – New clinical study results,confirm the high and ...
... - Antisense,Pharma today announced, that the abstract entitled,“Preliminary ... Melanoma, and Colorectal Carcinoma with the,TGF-beta2 Inhibitor AP ... 43rd Annual Meeting of the American Society of,Clinical ... Illinois,U.S.A, from June 1st - 5th. , In ...
Cached Medicine Technology:Gardasil Demonstrates Up to 100% Efficacy 2Gardasil Demonstrates Up to 100% Efficacy 3Gardasil Demonstrates Up to 100% Efficacy 4Gardasil Demonstrates Up to 100% Efficacy 5Gardasil Demonstrates Up to 100% Efficacy 6Gardasil Demonstrates Up to 100% Efficacy 7Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... 4 Franklin & Seidelmann,( http://www.franklin-seidelmann.com ... into the hospital sector with the,addition of three new ... -- Barnes-Kasson Hospital, Susquehanna, PA, ... -- Syringa General Hospital, Grangeville, ID, ...
... Feb. 4 Pulse Systems announced today ... the International,Organization for Standardization (ISO) quality systems ... "Achievement of these highly-regarded ... contract manufacturing services to the,medical device industry, ...
... 4 Kensey Nash Corporation (Nasdaq: KNSY ), ... technologies for a wide range of medical procedures, today announced ... Manager of Ramius LLC, from its Board of Directors.Mr. Smith ... was a member of the Corporate Governance and Nominating Committee ...
... UK, 04 February 2009 The journal ... has announced the winner of the 2008 David Horrobin ... and Jan van der Linden from the Karolinska Institute ... the risk of surgical site infection" was judged to ...
... With counterfeit and adulterated medicines posing an increasing ... the U.S. Pharmacopeial (USP) Convention today announces new standards ... involved in episodes of adulteration resulting in patient deaths. ... blood thinner heparin and the sweetener glycerin, comes on ...
... Omega-3s EPA/DHA and 170% Daily Requirement of Vitamin EPARAMUS, N.J., ... ) today announced that it will launch Smart Balance(TM) Milk ... areas and New England during the first quarter of 2009. ... sold in Florida and Georgia, tastes rich and creamy, is ...
Cached Medicine News:Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 2Health News:Franklin & Seidelmann Expands into Critical Access Hospital Market Provides 24 x 7 Teleradiology Service for Three New Clients 3Health News:Pulse Systems Receives Dual Certification Under ISO 13485:2003 and ISO 9001:2008 2Health News:Kensey Nash Announces Director Resignation 2Health News:USP announces new standards to protect patients from counterfeit and adulterated medicines 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 2Health News:Smart Balance to Bring Milk with More Taste and Less Fat to New York City and Albany Metro Areas and New England 3
Tapered Shaft Microscissors : Williams Curved SharpTipped Scissors...
Disposable Microscissors: Horizontal, Curved...
Disposable Microscissors: Horizontal, Straight...
Disposable Microscissors: Vertical, 90...
Medicine Products: